Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Carol Keohane, BSN, RN
Advertisement
Articles by Carol Keohane, BSN, RN
Advertisement
Latest Updated Articles
- Genomic Testing and Therapies for Breast Cancer in Clinical Practice
Published: May 15th 2011 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
3
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5
